Faeth Therapeutics, Inc.
NASDAQ:FTHBiotechnology
Healthcare
$8.72 +5.01%
+$1.43 today
- Market cap
- $224.79M
- Beta
- -0.31
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$34.65
52W Low $7.21High $37.90
Volume 0.33M
Average 0.12M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$22.29M
FY 2025 · Annual
Net Income
-$21.09M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 685K | 1.81M | 571K | 551K | 0 |
| Gross Profit | (685K) | (1.81M) | (571K) | (551K) | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 21.66M | 29.58M | 18.3M | 18.63M | 10.96M |
| Selling, General & Admin | 15.14M | 17.73M | 18.77M | 12.49M | 11.33M |
| Operating Expenses | 36.8M | 47.31M | 36.49M | 31.11M | 22.29M |
| Depreciation & Amortization | 685K | 1.81M | 3.68M | 551K | 139K |
| EBITDA | (35.44M) | (46.56M) | (33.39M) | (29.52M) | (20.91M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (37.48M) | (49.12M) | (37.06M) | (31.66M) | (22.29M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 800K | 1.78M | 3.62M | 2.55M | 1.24M |
| Interest Expense | 670K | 219K | 144K | 90K | 32K |
| Other Income / Expenses | 688K | 532K | 2.96M | 1.51M | 1.2M |
| Income Before Tax | (36.79M) | (48.59M) | (34.1M) | (30.16M) | (21.09M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (36.79M) | (48.59M) | (34.1M) | (30.16M) | (21.09M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (26.56) | (31.65) | (24.40) | (24.01) | (16.72) |
| EPS (Diluted) | (26.56) | (31.65) | (24.40) | (24.01) | (16.72) |
| 1.39M | 1.54M | 1.4M | 1.26M | 1.26M | |
| 1.39M | 1.54M | 1.4M | 1.26M | 1.26M |
FTH Earnings Waterfall · TTM
NASDAQ:FTH · Revenue to Net Income
Key Ratios
EPS$-141.65
Gross Margin0.0%
Net Margin23.5%
P/E Ratio-0.9
P/S Ratio-0.6
Analysis
-$4.9M of revenue converted into -$195.5M of net income for the selected period. Gross margin is 0.0% and net margin is 23.5%, showing how much revenue survives after costs and taxes. EPS is $-141.65, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| 8-K | Current report | Nov 3, 2026 | |
| S-8 | S-8 filing | Nov 3, 2026 |
How much revenue does FTH generate?
Faeth Therapeutics, Inc. (FTH) reported $0.00 of revenue in fiscal 2025.
Is FTH profitable?
Faeth Therapeutics, Inc. (FTH) reported -$21.09M of net income.
Continue the stock analysis
Jump to another research area for this company.